Connect
MJA
MJA

Glaucoma in perspective

Yu Xiang George Kong, Annie Gibbins and Anne Brooks
Med J Aust 2019; 210 (4): . || doi: 10.5694/mja2.50011
Published online: 4 March 2019

New technologies and collaborative care are improving the quality of life of patients with glaucoma

Glaucoma is one of the leading causes of irreversible blindness in the world, estimated to affect 66 million people worldwide and some 300 000 Australians.1,2 The majority of glaucoma patients present with progressive asymptomatic visual loss, with over 50% remaining undiagnosed.3 Annual costs of glaucoma to the health system in Australia are estimated to increase from $355 million in 2005 to $784 million by 2025.2 Management of this disease requires early detection, encouraging treatment adherence, improving patients’ quality of life and advancing medical research. To achieve this, strong collaboration is required between ophthalmologists, optometrists, orthoptists, pharmacists, general practitioners, patient advocacy groups like Glaucoma Australia and the Royal Australian and New Zealand College of Ophthalmologists, and funding bodies.

  • Yu Xiang George Kong1,2
  • Annie Gibbins3
  • Anne Brooks1,2

  • 1 Royal Victorian Eye and Ear Hospital, Melbourne, VIC
  • 2 Centre for Eye Research Australia, Melbourne, VIC
  • 3 Glaucoma Australia, Sydney, NSW

Correspondence: amvbrooks@bigpond.com

Acknowledgements: 

Yu Xiang George Kong is supported by an Ophthalmic Research Institute of Australia New Investigator Grant.

Competing interests:

Yu Xiang George Kong is Director of GLANCE Optical Pty Ltd.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

You do not have permission to add a response to this article.